2024
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease.
Adler J, Galanko J, Ammoury R, Benkov K, Bousvaros A, Boyle B, Cabrera J, Chun K, Dorsey J, Ebach D, Firestine A, Gulati A, Herfarth H, Jester T, Kaplan J, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Pashankar D, Pitch L, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Wali P, Kappelman M. HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. The American Journal Of Gastroenterology 2024 PMID: 39423015, DOI: 10.14309/ajg.0000000000003135.Peer-Reviewed Original ResearchHLA-DQA1*05Anti-drug antibodiesDQA1*05Anti-drug antibody developmentTreatment failureCrohn's diseaseAnti-TNFPositive patientsDevelopment of anti-drug antibodiesAnti-TNF treatment failureTumor necrosis factor antagonistsIndicator of treatment failureAnti-TNF monotherapyPediatric Crohn's diseaseIncreased treatment failureTrial of childrenYears of ageRandomized trial of childrenOral methotrexatePositive participantsRisk stratificationPediatric dataRandomized trialsIncreased riskPrimary outcomeLow Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease
Moses J, Adler J, Saeed S, Firestine A, Galanko J, Ammoury R, Bass D, Bass J, Bastidas M, Benkov K, Bousvaros A, Cabrera J, Chun K, Dorsey J, Ebach D, Gulati A, Herfarth H, Ivanova A, Jester T, Kaplan J, Kusek M, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Niklinska-Schirtz B, Olano K, Osaba L, Palomo P, Pashankar D, Pitch L, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Tung J, Wali P, Wohl D, Zikry M, Boyle B, Kappelman M. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease. Inflammatory Bowel Diseases 2024, izae239. PMID: 39418336, DOI: 10.1093/ibd/izae239.Peer-Reviewed Original ResearchTherapeutic drug levelsPatients treated with adalimumabPatients treated with infliximabHigher drug levelsAnti-TNF levelsMedian drug levelsTreatment failureCombination therapyReduce treatment failureDrug levelsLD-MTXLow-dose oral methotrexateAssociated with treatment failureCrohn's diseaseMonotherapy to combination therapyRisk of treatment failureAnti-tumor necrosis factorEffects of combination therapyCombination therapy armMaintenance of remissionAssociated with reduced riskPediatric Crohn's diseasePost hoc analysisAdalimumab initiationMaintenance therapyHigh Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease
Ebach D, Jester T, Galanko J, Firestine A, Ammoury R, Cabrera J, Bass J, Minar P, Olano K, Margolis P, Sandberg K, Linnville T, Kaplan J, Pitch L, Steiner S, Bass D, Moses J, Adler J, Gulati A, Wali P, Pashankar D, Ivanova A, Herfarth H, Wohl D, Benkov K, Strople J, Sullivan J, Tung J, Molle-Rios Z, Saeed S, Bousvaros A, Kappelman M. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease. The American Journal Of Gastroenterology 2024, 119: 1110-1116. PMID: 38445644, PMCID: PMC11150092, DOI: 10.14309/ajg.0000000000002741.Peer-Reviewed Original ResearchHigher body mass indexNormal body mass indexPediatric Crohn's diseaseBody mass indexAnti-TNF levelsInfliximab initiationTrough levelsTreatment failureObese patientsMass indexTime-to-treatment failureCrohn's diseaseResponse to anti-TNF therapyAssociated with treatment failureMonotherapy to combination therapyBody mass index groupsBody mass index categoriesPrescribed anti-TNFProactive drug monitoringAdalimumab-treated patientsDrug trough levelsAnti-TNF treatmentAnti-TNF therapyInfliximab trough levelsWeight-based dosing
2023
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial
Kappelman M, Wohl D, Herfarth H, Firestine A, Adler J, Ammoury R, Aronow J, Bass D, Bass J, Benkov K, Tobi C, Boccieri M, Boyle B, Brinkman W, Cabera J, Chun K, Colletti R, Dodds C, Dorsey J, Ebach D, Entrena E, Forrest C, Galanko J, Grunow J, Gulati A, Ivanova A, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Lipstein E, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Osaba L, Palomo P, Pappa H, Park K, Pashankar D, Pitch L, Robinson M, Samson C, Sandberg K, Schuchard J, Seid M, Shelly K, Steiner S, Strople J, Sullivan J, Tung J, Wali P, Zikry M, Weinberger M, Saeed S, Bousvaros A. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial. Gastroenterology 2023, 165: 149-161.e7. PMID: 37004887, PMCID: PMC10330864, DOI: 10.1053/j.gastro.2023.03.224.Peer-Reviewed Original ResearchConceptsPediatric Crohn's diseaseNecrosis factor inhibitorsPatient-reported outcomesAdverse eventsTreatment failureCombination therapyCrohn's diseaseSerious AEsFactor inhibitorsTumor necrosis factor inhibitorsAnti-drug antibody developmentAnti-TNF monotherapyCombination therapy armCrohn's disease therapyMethotrexate combination therapyTolerable safety profileLow-dose methotrexateMore adverse eventsSerious adverse eventsAnti-drug antibodiesPragmatic Randomized TrialDisease therapyLoss of responseOral methotrexateTherapy armUse, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti R, Network I, Adler J, Baron H, Cabrera J, Dorsey J, Dykes D, Ebach D, Garin‐Laflam M, Gold B, Grunow J, Higuchi L, Jester T, Lapsia S, Leibowitz I, Linvlle T, Morhardt T, Moses J, Moulton D, Nasiri‐Blomgren S, Niklinska‐Schirtz B, Ogunmola N, Palomo P, Park K, Pashankar D, Pasternak B, Radano M, Samson C, Sandberg K, Schaefer M, Shashidhar H, Steiner S, Sullivan J, Tomer G, Verstraete S. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort. Journal Of Pediatric Gastroenterology And Nutrition 2023, 76: 566-575. PMID: 36804501, PMCID: PMC10097486, DOI: 10.1097/mpg.0000000000003734.Peer-Reviewed Original ResearchConceptsCrohn's diseaseUlcerative colitisLoss of responseFirst biologicSubsequent biologicsBiologic agentsBiologic medicationsBiologic treatmentAnti-tumor necrosis factor agentsUpper gastrointestinal tract involvementGastrointestinal tract involvementNecrosis factor agentsActive Crohn's diseaseFirst biologic agentIBD cohortInitial biologicSecond biologicTract involvementCorticosteroid useFactor agentsPediatric IBDBiologic initiationDisease courseUnivariate analysisSevere disease
2022
Isolated Terminal Ileitis in Children
Alper A, Bennett A, Rottmann D, Morotti R, Escalera S, Phatak U, Pashankar D. Isolated Terminal Ileitis in Children. Journal Of Pediatric Gastroenterology And Nutrition 2022, 76: 338-342. PMID: 36729703, DOI: 10.1097/mpg.0000000000003679.Peer-Reviewed Original ResearchConceptsCrohn's diseaseTerminal ileitisAbnormal C-reactive protein levelsC-reactive protein levelsBowel wall thickeningLong-term outcomesRadiological evidenceRadiological featuresSevere inflammationPediatric literatureHigh prevalenceIleitisWall thickeningProtein levelsChildrenPrevalenceAdultsColonoscopyInflammationEndoscopicHistologicDiseaseMonths
2021
Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease
Miller T, Schuchard J, Carle A, Forrest C, Kappelman M, Group T, Adler J, Ammoury R, Bass D, Bass J, Benkov K, Bousvaros A, Boyle B, Cabrera J, Colletti R, Dorsey J, Ebach D, Firestine A, Gulati A, Hoffenberg E, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Margolis P, Minar P, Rios Z, Moses J, Palomo P, Pappa H, Pashankar D, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Tung J, Wali P. Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease. The Journal Of Pediatrics 2021, 242: 86-92.e3. PMID: 34740588, PMCID: PMC8882140, DOI: 10.1016/j.jpeds.2021.10.053.Peer-Reviewed Original ResearchConceptsPROMIS pediatric measuresMulticenter pragmatic trialCrohn's diseasePediatric measuresClinical trialsDisease activityPain interferencePragmatic trialPediatric patient-reported outcome measuresPatient-reported outcome measuresLower PRO scoresOutcomes Measurement Information System (PROMIS) pediatric measuresPRO score changesSteroid-free remissionPediatric Crohn's diseaseChronic pediatric illnessPragmatic clinical trialsClinical trial endpointsUse of patientPediatric patientsStudy endpointClinical outcomesPRO scoresTrial endpointsPRO endpoints
2020
Continued Statural Growth in Older Adolescents and Young Adults With Crohn’s Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure
Gupta N, Liu C, King E, Sylvester F, Lee D, Boyle B, Trauernicht A, Chen S, Colletti R, Adler J, Ali S, Al-Nimr A, Ayers T, Baron H, Beasley G, Benkov K, Cabrera J, Cho-Dorado M, Dancel L, Di Palma J, Dorsey J, Gulati A, Hellmann J, Higuchi L, Hoffenberg E, Israel E, Jester T, Kiparissi F, Konikoff M, Leibowitz I, Maheshwari A, Moulton D, Moses J, Ogunmola N, Palmadottir J, Pandey A, Pappa H, Pashankar D, Pasternak B, Patel A, Quiros J, Rountree C, Samson C, Sandberg K, Schoen B, Steiner S, Stephens M, Sudel B, Sullivan J, Suskind D, Tomer G, Tung J, Verstraete S. Continued Statural Growth in Older Adolescents and Young Adults With Crohn’s Disease and Ulcerative Colitis Beyond the Time of Expected Growth Plate Closure. Inflammatory Bowel Diseases 2020, 26: 1880-1889. PMID: 31968095, DOI: 10.1093/ibd/izz334.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseGrowth plate closureUlcerative colitisCrohn's diseaseAge 15 yearsPlate closureStatural growthHeight gainNutrition Examination SurveyFinal adult heightHeight velocity curvesTotal height gainBowel diseasePediatric patientsExamination SurveyPatient transitionsNational HealthAdult carePatientsDisease statusAdult heightDiseaseYoung adultsGrowth plateRadiographic closure
2017
Correlation of Erythrocyte Sedimentation Rate and C‐Reactive Protein With Pediatric Inflammatory Bowel Disease Activity
Alper A, Zhang L, Pashankar DS. Correlation of Erythrocyte Sedimentation Rate and C‐Reactive Protein With Pediatric Inflammatory Bowel Disease Activity. Journal Of Pediatric Gastroenterology And Nutrition 2017, 65: e25-e27. PMID: 27741061, DOI: 10.1097/mpg.0000000000001444.Peer-Reviewed Original ResearchConceptsErythrocyte sedimentation rateC-reactive proteinInflammatory bowel diseaseDisease activityCrohn's diseaseBowel diseaseCRP valuesInflammatory bowel disease activitySmall bowel Crohn's diseaseUlcerative colitis disease activityNormal erythrocyte sedimentation rateBowel disease activityRadiographic disease activityHistologic activitySedimentation rateUlcerative colitisDiseaseDiagnosisChildrenColitisActivityOP025 Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
King E, Park K, Pashankar D, Shashidhar H, Sudel B, Eichner S, Chen S, Pratt J, Colletti R, Burlington I. OP025 Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice. Journal Of Crohn's And Colitis 2017, 11: s15-s16. DOI: 10.1093/ecco-jcc/jjx002.024.Peer-Reviewed Original ResearchSteroid-free clinical remissionSteroid-free clinical responseDisease activity indexClinical remissionClinical responseCrohn's diseaseClinical practiceATNF therapyCare visitsDisease patientsShort Pediatric Crohn's Disease Activity IndexAnti-tumor necrosis factor agentsExact testPediatric Crohn's Disease Activity IndexPediatric Crohn's disease patientsCrohn's Disease Activity IndexMultivariable logistic regression analysisConcomitant immunomodulator therapyNecrosis factor agentsPhysician global assessmentRetrospective cohort studyPediatric Crohn's diseaseCrohn's disease patientsNumber of patientsDuration of treatment
2016
Prevalence and Clinical, Endoscopic, and Pathological Features of Duodenitis in Children
Alper A, Hardee S, Rojas‐Velasquez D, Escalera S, Morotti RA, Pashankar DS. Prevalence and Clinical, Endoscopic, and Pathological Features of Duodenitis in Children. Journal Of Pediatric Gastroenterology And Nutrition 2016, 62: 314-316. PMID: 26252915, PMCID: PMC4724230, DOI: 10.1097/mpg.0000000000000942.Peer-Reviewed Original ResearchConceptsAssociated gastritisEndoscopic appearancePathological featuresCeliac diseaseClinical diagnosisDiagnosis of duodenitisPositive celiac serologyInflammatory bowel diseaseHelicobacter pylori infectionPatient's clinical diagnosisCeliac serologyAbdominal painUpper endoscopyVillous changesBowel diseaseCommon indicationUlcerative colitisCommon etiologyCrohn's diseasePylori infectionPathology reportsDuodenitisCommon causeEndoscopic dataLarge cohort
2014
Histopathology of Duodenal Mucosal Lesions in Pediatric Patients with Inflammatory Bowel Disease: Statistical Analysis to Identify Distinctive Features
Hardee S, Alper A, Pashankar DS, Morotti RA. Histopathology of Duodenal Mucosal Lesions in Pediatric Patients with Inflammatory Bowel Disease: Statistical Analysis to Identify Distinctive Features. Pediatric And Developmental Pathology 2014, 17: 450-454. PMID: 25207874, DOI: 10.2350/14-07-1529-oa.1.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal tractVillous bluntingIntraepithelial lymphocytesPediatric patientsDuodenal lesionsDifferent etiopathogenesisUlcerative colitisCrohn's diseaseInflammatory bowel disease patientsCases of duodenitisDuodenal mucosal lesionsBowel disease patientsInflammatory bowel diseasePresence of granulomasAge-matched controlsLamina propria eosinophilsKruskal-Wallis testingCeliac groupDuodenal pathologyDuodenitis casesAssociated gastritisBowel diseaseCrypt hyperplasiaMucosal lesionsPediatric population